A psilocybin therapy trial therapy room COMPASS Pathways
Is psychedelic medicine finally ready to live up to the hype? Yesterday, promising results were announced from the largest clinical trial of psilocybin for depression to date. They suggest that, while psilocybin therapy is far from a panacea, it can help some people for whom current medicines are ineffective.
The study was led by Compass Pathways, a UK-based company that holds patents for two synthetic formulations of psilocybin, the active ingredient in magic mushrooms. It involved 233 people with treatment-resistant depression, meaning to be eligible they had to have tried two other…
